Terms: = Breast cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
1808 results:
1. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.
Lee M; Yoo TK; Chae BJ; Lee A; Cha YJ; Lee J; Ahn SG; Kang J
Sci Rep; 2024 May; 14(1):11278. PubMed ID: 38760384
[TBL] [Abstract] [Full Text] [Related]
2. circATAD2 mitigates CD8
Zhang Z; Huo W; Li J
Cancer Immunol Immunother; 2024 May; 73(7):130. PubMed ID: 38748254
[TBL] [Abstract] [Full Text] [Related]
3. Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
Marchese E; Demehri S
J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747288
[TBL] [Abstract] [Full Text] [Related]
4. Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
Kim SM; Park N; Park HB; Lee J; Chun C; Kim KH; Choi JS; Kim HJ; Choi S; Lee JH
PLoS One; 2024; 19(5):e0303433. PubMed ID: 38743676
[TBL] [Abstract] [Full Text] [Related]
5. EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer.
Zhang J; Yang J; Li X; Mao L; Zhang Y; Liu Y; Bao Y
Mol Genet Genomics; 2024 May; 299(1):51. PubMed ID: 38743077
[TBL] [Abstract] [Full Text] [Related]
6. Neoadjuvant radiotherapy in ER
Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
[TBL] [Abstract] [Full Text] [Related]
7. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
Zhao J; Liu Z; Yang K; Shen S; Peng J
Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
[TBL] [Abstract] [Full Text] [Related]
8. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy.
Blaya-Cánovas JL; Griñán-Lisón C; Blancas I; Marchal JA; Ramírez-Tortosa C; López-Tejada A; Benabdellah K; Cortijo-Gutiérrez M; Cano-Cortés MV; Graván P; Navarro-Marchal SA; Gómez-Morales J; Delgado-Almenta V; Calahorra J; Agudo-Lera M; Sagarzazu A; Rodríguez-González CJ; Gallart-Aragón T; Eich C; Sánchez-Martín RM; Granados-Principal S
Mol Cancer; 2024 May; 23(1):83. PubMed ID: 38730475
[TBL] [Abstract] [Full Text] [Related]
9. T-reg transcriptomic signatures identify response to check-point inhibitors.
Noblejas-López MDM; García-Gil E; Pérez-Segura P; Pandiella A; Győrffy B; Ocaña A
Sci Rep; 2024 May; 14(1):10396. PubMed ID: 38710724
[TBL] [Abstract] [Full Text] [Related]
10. [Efficacy analysis of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 inhibitor treatment in hormone receptor positive/human epidermal growth factor receptor 2-low metastatic breast cancer].
Liu B; Yuan Y; Li F; Li JB; Bian L; Wang T; Zhang SH; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1507-1513. PubMed ID: 38706058
[No Abstract] [Full Text] [Related]
11. PD-1/pd-l1 pathway: Current research in breast cancer.
Syamsu SA; Faruk M; Smaradania N; Sampepajung E; Pranoto AS; Irsandy F; Tammasse IFU
Breast Dis; 2024; 43(1):79-92. PubMed ID: 38701137
[TBL] [Abstract] [Full Text] [Related]
12. Genetically Edited Cascade Nanozymes for cancer Immunotherapy.
Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
[TBL] [Abstract] [Full Text] [Related]
13. Epithelial Expressed b7-h4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
14. [Evaluation of pd-l1 expression and intratumoral lymphocytic infiltration in triple-negative invasive breast carcinoma].
Barrios Barreto R; Silvera Redondo C; Garavito MDP; Ardila Pereira L
Medicina (B Aires); 2024; 84(2):227-235. PubMed ID: 38683507
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative breast cancer.
Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
[TBL] [Abstract] [Full Text] [Related]
16. IFI30 as a key regulator of pdl1 immunotherapy prognosis in breast cancer.
Li L; Fei Y; Dong T; Song Y; Chen X; Zhang H; Zhou H; Liang M; Tang J
Int Immunopharmacol; 2024 May; 133():112093. PubMed ID: 38669947
[TBL] [Abstract] [Full Text] [Related]
17. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/pd-l1 signaling.
Wang S; Li J; Hong S; Wang N; Xu S; Yang B; Zheng Y; Zhang J; Pan B; Hu Y; Wang Z
J Exp Clin Cancer Res; 2024 Apr; 43(1):121. PubMed ID: 38654356
[TBL] [Abstract] [Full Text] [Related]
18. Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages.
Xu L; Chen Y; Liu L; Hu X; He C; Zhou Y; Ding X; Luo M; Yan J; Liu Q; Li H; Lai D; Zou Z
PLoS Genet; 2024 Apr; 20(4):e1011235. PubMed ID: 38648200
[TBL] [Abstract] [Full Text] [Related]
19. Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer.
Liu X; Wang W; Chen B; Wang S
Aging (Albany NY); 2024 Apr; 16(8):7188-7216. PubMed ID: 38643462
[TBL] [Abstract] [Full Text] [Related]
20. Clinical relevance of glycosylation in triple negative breast cancer: a review.
Chakraborty M; Kaur J; Gunjan ; Kathpalia M; Kaur N
Glycoconj J; 2024 Apr; 41(2):79-91. PubMed ID: 38634956
[TBL] [Abstract] [Full Text] [Related]
[Next]
